AbbVie Inc. raised its full-year profit forecast as demand for its top-selling anti-inflammatory drugs, Rinvoq and Skyrizi, ...

Investing.com -- AbbVie (NYSE:ABBV) has lifted his full-year income forecast, as the pharmaceutical group said its was seeing "momentum" in its operations after third-quarter net revenue topped ...

Skyrizi holds biologic share leadership in approximately 30 countries and boasts a “best-in-class profile” that presents a “very high bar” for rivals, AbbVie's chief commercial officer ...

💰💸 Don’t miss the move: SIGN UP for TheStreet’s FREE Daily newsletter 💰💸 AbbVie CEO Robert Michael told analysts during the company's second-quarter earnings call in July that ...

which is $1.3 billion ahead of AbbVie’s initial expectations. Skyrizi’s impressive clinical results have allowed it to achieve in-play biologic share leadership in 30 key countries in ...

By investing in research and development and making smart acquisitions. AbbVie CEO Rob Michael said in the Q3 earnings call that the company expects Humira's successor products, Skyrizi and Rinvoq ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Michael, chief executive officer, AbbVie. Skyrizi and Rinvoq revenues were up 50.8% Y/Y to $3.2B and 45.3% to $1.6B, respectively, during the quarter, as the immunology portfolio generated over $ ...

"We delivered another quarter of strong commercial execution and significant pipeline progress," said AbbVie CEO Robert A. Michael. "Based upon the momentum of AbbVie's business and our confidence ...

Investing.com -- AbbVie (NYSE:ABBV) has lifted his full-year income forecast, as the pharmaceutical group said its was seeing "momentum" in its operations after third-quarter net revenue topped ...